2022
Development of patient derived organoids for cancer drug screening applications
Baskar G, Palaniyandi T, Viswanathan S, Rajendran B, Ravi M, Sivaji A. Development of patient derived organoids for cancer drug screening applications. Acta Histochemica 2022, 124: 151895. PMID: 35486967, DOI: 10.1016/j.acthis.2022.151895.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsDrug Evaluation, PreclinicalEarly Detection of CancerHumansNeoplasmsOrganoidsConceptsPre-clinical modelsEx vivo tissue cultureDevelopment of patientsCancer researchStem cellsVivo tissue culturePatient responseAbnormal cell growthProgenitor cellsHigh-throughput drug screeningVivo propertiesOrganoidsHuman organoidsPluripotent stem cellsCell growthDrug screening applicationsDrug screeningThroughput drug screeningEmbryonic stem cellsTissueCellsTissue cultureEffective recapitulationPatientsClinic
2021
Molecular landscape and subtype-specific therapeutic response of nasopharyngeal carcinoma revealed by integrative pharmacogenomics
Ding R, Chen P, Rajendran B, Lyu X, Wang H, Bao J, Zeng J, Hao W, Sun H, Wong A, Valecha M, Yang E, Su S, Choi T, Liu S, Chan K, Yang L, Wu J, Miao K, Chen Q, Shim J, Xu X, Deng C. Molecular landscape and subtype-specific therapeutic response of nasopharyngeal carcinoma revealed by integrative pharmacogenomics. Nature Communications 2021, 12: 3046. PMID: 34031426, PMCID: PMC8144567, DOI: 10.1038/s41467-021-23379-3.Peer-Reviewed Original ResearchConceptsSarcomatoid carcinomaEpithelial-mesenchymal transitionNasopharyngeal carcinomaCarcinoma subtypesNeck cancer typesPatient-derived organoidCRT regimensDistinct molecular featuresMalignant headHigh morbidityTreatment regimensTherapeutic responseEC subtypesPathogenic mechanismsDrug responsivenessEGFR inhibitorsNPC subtypesCancer typesSubtypesCarcinomaPrecision oncologyDrug testsMolecular landscapeRegimensMicrotubule inhibitors